Labcorp Holdings Inc.
LH - NYSE - $254.12 ▼ -%1.52
-
Earnings Thu 23 Jul

Labcorp opens the
books on Thursday evening.

4 analysts' median target is $300[FMP target], stock is $254, +18.1% upside potential. After Q1 +3.9% EPS beat[FMP earnings], the stock moved -0.4%.

↓ summary below
Quick Take - in 40 seconds
B+
BUY Council 2/6 - Moonshot 36

B+ = MoonshotScore 36[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $3.7B[FMP est], EPS $4.78[FMP est]. 8 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$4.78 EPS Estimate Last year $4.07 - +10% YoY YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 EPS +3.9% beat[FMP] but the stock -0.4% D+1[FMP D+1]. Julia Wang promised $121.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[Julia Wang capex transcript].

Watchlist

5 metrics stand out this quarter.

$781 million Investor Focus

Biopharma Growth

biopharma_growth

Biopharma Laboratory Services (BLS) revenue grew by 8.2%, with central labs driving the growth.

"Biopharma Laboratory Services revenue grew to $781 million, up 8.2% compared to last year, which includes a 5.5% benefit from foreign currency translation."

- Julia Wang, CFO - Q1 FY26 Earnings Call - April 30, 2026
5.8% Investor Focus

Revenue Growth

revenue_growth

Labcorp had a strong start to the year, achieving a revenue increase of 5.8% in the first quarter.

"In the first quarter, enterprise revenue grew 5.8% and enterprise adjusted operating margin expanded more than 30 basis points to 14.4%."

- Julia Wang, CFO - Q1 FY26 Earnings Call - April 30, 2026
$30 million Expectation / Guide

Fy26 Guidance Increase

fy26_guidance_increase

Labcorp is raising its revenue and earnings per share (EPS) expectations for 2026.

"We are raising the midpoint of the enterprise revenue range by approximately $30 million and the midpoint of the EPS range by $0.13."

- Julia Wang, CFO - Q1 FY26 Earnings Call - April 30, 2026
5% Investor Focus

Diagnostics Growth

diagnostics_growth

Diagnostic Laboratories delivered another strong quarter with 5% revenue growth.

"Diagnostic Laboratories delivered another strong quarter with 5% revenue growth to $2.8 billion."

- Julia Wang, CFO - Q1 FY26 Earnings Call - April 30, 2026
$8.6 billion Investor Focus

Bls Backlog

bls_backlog

The BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months.

"Our BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months."

- Julia Wang, CFO - Q1 FY26 Earnings Call - April 30, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 36 / 100

9-pillar methodology. News Sentiment strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth0.0Q1 vs Q2: growth slowing (+0.3%, below threshold)
Gross Margin3.0Q1: low margin (26.5%, capital-intensive or commodity)
Operating Leverage1.0op margin average (10.9%)
Cash Runway6.0FCF positive but absorbed ($0.1B vs $0.1B CapEx)
R&D Intensity3.0low R&D investment (0.0%, weak innovation)
Price Momentum4.0RSI 37.7 weak momentum, 50d below
News Sentiment8.0strong buy consensus (75%)
Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +18.1%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 38
Klarman value - target upside +18.1%
Buffett quality - ROE score 4/5
Munger valuation - target upside +18.1%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
37.7 RSI 37.7 weak momentum, 50d below
MACD
-4.90 price below 50d - resistance dominant
50d MA
$267 stock 4.9% below - short-term resistance
200d MA
$269 stock 5.5% below - long-term pressure
Volume (10d)
-36% decrease - low participation
Resistance
$300
Analyst median target - upgrade trigger if broken
Current
$254
Pre-earnings position
Support
$229
Invalidation - close below this is a technical breakdown
Pattern
Range
$229-$300 band - earnings breakout/breakdown trigger

Past Performance

Labcorp beat expectations in the last 8 quarters.

BEAT
Q2 FY25
$4.35 vs $4.17 est - -1.0%
BEAT
Q3 FY25
$4.18 vs $4.13 est - -4.4%
BEAT
Q4 FY25
$4.07 vs $3.95 est - +0.8%
BEAT
Q1 FY26
$4.25 vs $4.09 est - -0.4%

Q1 (April 30, 2026): EPS $4.25 vs $4.09 est[FMP], +3.9% beat. D+1 movement: -0.4%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $4.64 (no guidance)

Q1: EPS $4.25 vs $4.09 beat[FMP], stock -0.4% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $121.0M[FMP cashflow]. Q1 op margin 10.9%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $4.78 + CapEx discipline
Threshold: EPS > $4.78[FMP est].
Target: Break above median target $300[FMP target]; high target $334[FMP] upper bound.
Scenario B - In-Line
EPS approx $4.78 + CapEx < $121.0M
Threshold: EPS approx $4.78[FMP est], Q4 CapEx < $121.0M[FMP].
Target: Consolidation in the band between current $254[FMP] and median $300[FMP].
Scenario C - Miss
EPS < $4.64 or CapEx >= $121.0M
Threshold: EPS < $4.64[FMP estx0.97].
Target: Current $254 below SMA200 $269[FMP], if rejection continues, $229[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 4 analysts say?

Wall Street Consensus
$300
12-month median target price (+18.1% upside potential)
15
BUY
5
HOLD
0
SELL
Risk Management
$229
Invalidation level - critical support threshold
$267 - 50-day MA (below, -4.9%)
$269 - 200-day MA (below, -5.5%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - LH Q4 FY26
B+

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $4.78[FMP], CapEx threshold "below $121.0M"[Julia Wang]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days LH dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 23, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 24, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 6, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 23, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the LH earnings preview cover?

This LH (LH) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in LH earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.